<?xml version="1.0" encoding="UTF-8"?><TED_EXPORT xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://publications.europa.eu/resource/schema/ted/R2.0.9/publication" xmlns:n2016="http://publications.europa.eu/resource/schema/ted/2016/nuts" xsi:schemaLocation="http://publications.europa.eu/resource/schema/ted/R2.0.9/publication TED_EXPORT.xsd" VERSION="R2.0.9.S03.E01" DOC_ID="539765-2019" EDITION="2019220"><TECHNICAL_SECTION><RECEPTION_ID>19-552076-001</RECEPTION_ID><DELETION_DATE>20200219</DELETION_DATE><FORM_LG_LIST>EN </FORM_LG_LIST><COMMENTS>From Convertor</COMMENTS></TECHNICAL_SECTION><LINKS_SECTION><XML_SCHEMA_DEFINITION_LINK xlink:type="simple" xlink:href="http://ted.europa.eu" xlink:title="TED WEBSITE"/><OFFICIAL_FORMS_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/><FORMS_LABELS_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/><ORIGINAL_CPV_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/><ORIGINAL_NUTS_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/></LINKS_SECTION><CODED_DATA_SECTION><REF_OJS><COLL_OJ>S</COLL_OJ><NO_OJ>220</NO_OJ><DATE_PUB>20191114</DATE_PUB></REF_OJS><NOTICE_DATA><NO_DOC_OJS>2019/S 220-539765</NO_DOC_OJS><URI_LIST><URI_DOC LG="EN">http://ted.europa.eu/udl?uri=TED:NOTICE:539765-2019:TEXT:EN:HTML</URI_DOC></URI_LIST><LG_ORIG>EN</LG_ORIG><ISO_COUNTRY VALUE="UK"/><IA_URL_GENERAL>https://nhsengland.bravosolution.co.uk</IA_URL_GENERAL><ORIGINAL_CPV CODE="33600000">Pharmaceutical products</ORIGINAL_CPV><n2016:PERFORMANCE_NUTS CODE="UKK">SOUTH WEST (ENGLAND)</n2016:PERFORMANCE_NUTS><n2016:PERFORMANCE_NUTS CODE="UKJ">SOUTH EAST (ENGLAND)</n2016:PERFORMANCE_NUTS><n2016:PERFORMANCE_NUTS CODE="UKI">LONDON</n2016:PERFORMANCE_NUTS><n2016:PERFORMANCE_NUTS CODE="UKH">EAST OF ENGLAND</n2016:PERFORMANCE_NUTS><n2016:PERFORMANCE_NUTS CODE="UKG">WEST MIDLANDS (ENGLAND)</n2016:PERFORMANCE_NUTS><n2016:PERFORMANCE_NUTS CODE="UKF">EAST MIDLANDS (ENGLAND)</n2016:PERFORMANCE_NUTS><n2016:PERFORMANCE_NUTS CODE="UKE">YORKSHIRE AND THE HUMBER</n2016:PERFORMANCE_NUTS><n2016:PERFORMANCE_NUTS CODE="UKD">NORTH WEST (ENGLAND)</n2016:PERFORMANCE_NUTS><n2016:PERFORMANCE_NUTS CODE="UKC">NORTH EAST (ENGLAND)</n2016:PERFORMANCE_NUTS><n2016:CA_CE_NUTS CODE="UK">UNITED KINGDOM</n2016:CA_CE_NUTS><n2016:TENDERER_NUTS CODE="UK">UNITED KINGDOM</n2016:TENDERER_NUTS><VALUES><VALUE TYPE="PROCUREMENT_TOTAL" CURRENCY="GBP">14790000.00</VALUE></VALUES></NOTICE_DATA><CODIF_DATA><DS_DATE_DISPATCH>20191111</DS_DATE_DISPATCH><AA_AUTHORITY_TYPE CODE="1">Ministry or any other national or federal authority</AA_AUTHORITY_TYPE><TD_DOCUMENT_TYPE CODE="V">Voluntary ex ante transparency notice</TD_DOCUMENT_TYPE><NC_CONTRACT_NATURE CODE="2">Supplies</NC_CONTRACT_NATURE><PR_PROC CODE="T">Negotiated without a prior call for competition</PR_PROC><RP_REGULATION CODE="5">European Union, with participation by GPA countries</RP_REGULATION><TY_TYPE_BID CODE="9">Not applicable</TY_TYPE_BID><AC_AWARD_CRIT CODE="Z">Not specified</AC_AWARD_CRIT><MA_MAIN_ACTIVITIES CODE="H">Health</MA_MAIN_ACTIVITIES><HEADING>01B15</HEADING><INITIATOR>01</INITIATOR></CODIF_DATA></CODED_DATA_SECTION><TRANSLATION_SECTION><ML_TITLES><ML_TI_DOC LG="BG"><TI_CY>Обединено кралство</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Фармацевтични продукти</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="CS"><TI_CY>Spojené království/Velká Británie</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Léčivé přípravky a zdravotnické prostředky</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="DA"><TI_CY>Forenede Kongerige, Det</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Lægemidler</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="DE"><TI_CY>das Vereinigte Königreich</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Arzneimittel</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="EL"><TI_CY>Ηνωμένο Βασίλειο</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Φαρμακευτικά προϊόντα</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="EN"><TI_CY>United Kingdom</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Pharmaceutical products</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="ES"><TI_CY>Reino Unido</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Productos farmacéuticos</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="ET"><TI_CY>Suurbritannia / Ühendkuningriik</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Ravimid</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="FI"><TI_CY>Yhdistynyt kuningaskunta</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Farmaseuttiset tuotteet</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="FR"><TI_CY>Royaume-Uni</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Produits pharmaceutiques</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="GA"><TI_CY>Ríocht Aontaithe, an</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Pharmaceutical products</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="HR"><TI_CY>Ujedinjena Kraljevina</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Farmaceutski proizvodi</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="HU"><TI_CY>Egyesült Királyság</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Gyógyszerészeti termékek</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="IT"><TI_CY>Regno Unito</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Prodotti farmaceutici</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="LT"><TI_CY>Jungtinė Karalystė, Didžioji Britanija</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Farmacijos produktai</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="LV"><TI_CY>Apvienotā Karaliste</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Farmācijas izstrādājumi</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="MT"><TI_CY>Ir-Renju Unit</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Prodotti farmaċewtiċi</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="NL"><TI_CY>Verenigd Koninkrijk</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Farmaceutische producten</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="PL"><TI_CY>Zjednoczone Królestwo</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Produkty farmaceutyczne</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="PT"><TI_CY>Reino Unido</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Produtos farmacêuticos</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="RO"><TI_CY>Regatul Unit</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Produse farmaceutice</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="SK"><TI_CY>Spojené kráľovstvo</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Farmaceutické výrobky</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="SL"><TI_CY>Združeno kraljestvo</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Farmacevtski proizvodi</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="SV"><TI_CY>Förenade kungariket</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Läkemedel</P></TI_TEXT></ML_TI_DOC></ML_TITLES><ML_AA_NAMES><AA_NAME LG="EN">The NHS Commissioning Board (operating Under the name of NHS England)</AA_NAME></ML_AA_NAMES></TRANSLATION_SECTION><FORM_SECTION><F15_2014 CATEGORY="ORIGINAL" FORM="F15" LG="EN"><LEGAL_BASIS VALUE="32014L0024"/><CONTRACTING_BODY><ADDRESS_CONTRACTING_BODY><OFFICIALNAME>The NHS Commissioning Board (operating Under the name of NHS England)</OFFICIALNAME><ADDRESS>2nd Floor, Rutland House</ADDRESS><TOWN>Runcorn</TOWN><POSTAL_CODE>WA7 2ES</POSTAL_CODE><COUNTRY VALUE="UK"/><E_MAIL>michelle.clarke6@nhs.net</E_MAIL><n2016:NUTS CODE="UK"/><URL_GENERAL>https://nhsengland.bravosolution.co.uk</URL_GENERAL></ADDRESS_CONTRACTING_BODY><CA_TYPE VALUE="MINISTRY"/><CA_ACTIVITY VALUE="HEALTH"/></CONTRACTING_BODY><OBJECT_CONTRACT><TITLE><P>NHS Framework Agreement for Enoxaparin Sodium (Inhixa) for All Regions</P></TITLE><REFERENCE_NUMBER>CM/PHR/19/5585</REFERENCE_NUMBER><CPV_MAIN><CPV_CODE CODE="33600000"/></CPV_MAIN><TYPE_CONTRACT CTYPE="SUPPLIES"/><SHORT_DESCR><P>NHS framework agreement for Enoxaparin (Inhixa) – all regions</P><P>Offer reference number: CM/PHR/19/5585</P><P>Period of framework agreement: North of England (NOFE) 1.1.2020 – 29.2.2020, South of England (SOFE) 1.1.2020 – 31.8.2020, Midlands and East (MAE) 1.1.2020 – 28.2.2021, London 1.1.2020 – 31.8.2021 all with an option to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months.</P></SHORT_DESCR><VAL_TOTAL CURRENCY="GBP">14790000.00</VAL_TOTAL><NO_LOT_DIVISION/><OBJECT_DESCR ITEM="1"><n2016:NUTS CODE="UKC"/><n2016:NUTS CODE="UKD"/><n2016:NUTS CODE="UKE"/><n2016:NUTS CODE="UKF"/><n2016:NUTS CODE="UKG"/><n2016:NUTS CODE="UKH"/><n2016:NUTS CODE="UKI"/><n2016:NUTS CODE="UKJ"/><n2016:NUTS CODE="UKK"/><MAIN_SITE><P>Pharmaceutical buying groups in the NHS in England as of Tuesday 5<FT TYPE="SUP">th</FT> November</P><P>https://www.gov.uk/government/publications/pharmaceutical-buying-groups-in-the-nhs</P></MAIN_SITE><SHORT_DESCR><P>NHS framework agreement for Enoxaparin (Inhixa) – all regions</P><P>Offer reference number: CM/PHR/19/5585</P><P>Period of framework agreement: North of England (NOFE) 1.1.2020 – 29.2.2020, South of England (SOFE) 1.1.2020 – 31.8.2020, Midlands and East (MAE) 1.1.2020 – 28.2.2021, London 1.1.2020 – 31.8.2021 all with an option to extend (at the authority’s discretion) for a period or periods up to a total of 12 months.</P></SHORT_DESCR><NO_OPTIONS/><NO_EU_PROGR_RELATED/></OBJECT_DESCR></OBJECT_CONTRACT><PROCEDURE><DIRECTIVE_2014_24_EU><PT_NEGOTIATED_WITHOUT_PUBLICATION><D_ACCORDANCE_ARTICLE><D_MANUF_FOR_RESEARCH CTYPE="SUPPLIES"/><D_EXTREME_URGENCY/></D_ACCORDANCE_ARTICLE><D_JUSTIFICATION><P>Supplies or services can be supplied only by a particular economic operator and no reasonable alternative or substitute exists.</P><P>There is an urgent need to secure continuity of supply in a volatile market subject to significant product shortages.</P></D_JUSTIFICATION></PT_NEGOTIATED_WITHOUT_PUBLICATION></DIRECTIVE_2014_24_EU><FRAMEWORK/><CONTRACT_COVERED_GPA/></PROCEDURE><AWARD_CONTRACT ITEM="1"><CONTRACT_NO>CM/PHR/19/5585</CONTRACT_NO><LOT_NO>1</LOT_NO><TITLE><P>NHS Framework Agreement for Enoxaparin Sodium (Inhixa) for All Regions</P></TITLE><AWARDED_CONTRACT><DATE_CONCLUSION_CONTRACT>2019-11-04</DATE_CONCLUSION_CONTRACT><CONTRACTORS><NO_AWARDED_TO_GROUP/><CONTRACTOR><ADDRESS_CONTRACTOR><OFFICIALNAME>Techdow Pharma England Ltd</OFFICIALNAME><ADDRESS>Surrey Technology Centre Surrey Research Park, 40 Occam Road</ADDRESS><TOWN>Guildford</TOWN><POSTAL_CODE>GU2 7YG</POSTAL_CODE><COUNTRY VALUE="UK"/><n2016:NUTS CODE="UK"/></ADDRESS_CONTRACTOR><SME/></CONTRACTOR></CONTRACTORS><VALUES><VAL_TOTAL CURRENCY="GBP">14790000.00</VAL_TOTAL></VALUES><LIKELY_SUBCONTRACTED/></AWARDED_CONTRACT></AWARD_CONTRACT><COMPLEMENTARY_INFO><INFO_ADD><P>Supplies or services can be supplied only by a particular economic operator and no reasonable alternative or substitute exists.</P><P>There is an urgent need to secure continuity of supply in a volatile market subject to significant product shortages.</P></INFO_ADD><ADDRESS_REVIEW_BODY><OFFICIALNAME>The Royal Courts of Justice</OFFICIALNAME><TOWN>London or any other district registry of the High Court</TOWN><COUNTRY VALUE="UK"/></ADDRESS_REVIEW_BODY><DATE_DISPATCH_NOTICE>2019-11-11</DATE_DISPATCH_NOTICE></COMPLEMENTARY_INFO></F15_2014></FORM_SECTION></TED_EXPORT>